The UK charity for Waldenstrom’s macroglobulinaemia – a rare type of blood cancer

Support Line: 0300 373 8500

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

Understanding the dosage and safety of a new type of treatment

Main Aims

This study aims to understand how a drug called Sonrotoclax responds in people with certain types of lymphoma.
Researchers are looking to see how safe and effective the drug is, as well as understanding the best dosage. Patients will either be given Sonrotoclax by itself or in combination with other drugs.

This study is on-going but currently closed to recruitment.

Recruitment Criteria

• A confirmed diagnosis of WM

Recruitment status: Not Recruiting

Sponsor: BeiGene

Expected to end: 30/08/2027

Phases: Phase 1